Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis

Rakesh, David F. Bruhn, Michael S. Scherman, Lisa K. Woolhiser, Dora B. Madhura, Marcus M. Maddox, Aman P. Singh, Robin B. Lee, Julian G. Hurdle, Michael R. McNeil, Anne J. Lenaerts, Bernd Meibohm, Richard E. Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some potential for development as therapeutics against dormant TB bacilli. In previous studies, the pharmacokinetic properties of nitrofuranyl isoxazolines were improved by incorporation of the outer ring elements of the antitubercular nitroimidazole OPC-67683. This successfully increased stability of the resulting pentacyclic nitrofuran lead compound Lee1106 (referred to herein as 9a). In the current study, we report the synthesis and antimicrobial properties of 9a and panel of 9a analogs, which were developed to increase oral bioavailability. These hybrid nitrofurans remained potent inhibitors of Mycobacterium tuberculosis with favorable selectivity indices (>150) and a narrow spectrum of activity. In vivo, the pentacyclic nitrofuran compounds showed long half-lives and high volumes of distribution. Based on pharmacokinetic testing and lack of toxicity in vivo, 9a remained the series lead. 9a exerted a lengthy post antibiotic effect and was highly active against nonreplicating M. tuberculosis grown under hypoxia. 9a showed a low potential for cross resistance to current antitubercular agents, and a mechanism of activation distinct from pre-clinical tuberculosis candidates PA-824 and OPC-67683. Together these studies show that 9a is a nanomolar inhibitor of actively growing as well as nonreplicating M. tuberculosis.

Original languageEnglish (US)
Article numbere87909
JournalPloS one
Volume9
Issue number2
DOIs
StatePublished - Feb 5 2014

Fingerprint

Nitrofurans
nitrofurans
Mycobacterium tuberculosis
nitroimidazoles
Antitubercular Agents
Nitroimidazoles
Pharmacokinetics
pharmacokinetics
Lead compounds
cross resistance
Bacilli
anti-infective properties
tuberculosis
Bacillus
Biological Availability
half life
Toxicity
bioavailability
hypoxia
mouth

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Rakesh, Bruhn, D. F., Scherman, M. S., Woolhiser, L. K., Madhura, D. B., Maddox, M. M., ... Lee, R. E. (2014). Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PloS one, 9(2), [e87909]. https://doi.org/10.1371/journal.pone.0087909

Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. / Rakesh; Bruhn, David F.; Scherman, Michael S.; Woolhiser, Lisa K.; Madhura, Dora B.; Maddox, Marcus M.; Singh, Aman P.; Lee, Robin B.; Hurdle, Julian G.; McNeil, Michael R.; Lenaerts, Anne J.; Meibohm, Bernd; Lee, Richard E.

In: PloS one, Vol. 9, No. 2, e87909, 05.02.2014.

Research output: Contribution to journalArticle

Rakesh, Bruhn, DF, Scherman, MS, Woolhiser, LK, Madhura, DB, Maddox, MM, Singh, AP, Lee, RB, Hurdle, JG, McNeil, MR, Lenaerts, AJ, Meibohm, B & Lee, RE 2014, 'Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis', PloS one, vol. 9, no. 2, e87909. https://doi.org/10.1371/journal.pone.0087909
Rakesh ; Bruhn, David F. ; Scherman, Michael S. ; Woolhiser, Lisa K. ; Madhura, Dora B. ; Maddox, Marcus M. ; Singh, Aman P. ; Lee, Robin B. ; Hurdle, Julian G. ; McNeil, Michael R. ; Lenaerts, Anne J. ; Meibohm, Bernd ; Lee, Richard E. / Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. In: PloS one. 2014 ; Vol. 9, No. 2.
@article{9bdc03887013462bba270a557cb2d860,
title = "Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis",
abstract = "The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some potential for development as therapeutics against dormant TB bacilli. In previous studies, the pharmacokinetic properties of nitrofuranyl isoxazolines were improved by incorporation of the outer ring elements of the antitubercular nitroimidazole OPC-67683. This successfully increased stability of the resulting pentacyclic nitrofuran lead compound Lee1106 (referred to herein as 9a). In the current study, we report the synthesis and antimicrobial properties of 9a and panel of 9a analogs, which were developed to increase oral bioavailability. These hybrid nitrofurans remained potent inhibitors of Mycobacterium tuberculosis with favorable selectivity indices (>150) and a narrow spectrum of activity. In vivo, the pentacyclic nitrofuran compounds showed long half-lives and high volumes of distribution. Based on pharmacokinetic testing and lack of toxicity in vivo, 9a remained the series lead. 9a exerted a lengthy post antibiotic effect and was highly active against nonreplicating M. tuberculosis grown under hypoxia. 9a showed a low potential for cross resistance to current antitubercular agents, and a mechanism of activation distinct from pre-clinical tuberculosis candidates PA-824 and OPC-67683. Together these studies show that 9a is a nanomolar inhibitor of actively growing as well as nonreplicating M. tuberculosis.",
author = "Rakesh and Bruhn, {David F.} and Scherman, {Michael S.} and Woolhiser, {Lisa K.} and Madhura, {Dora B.} and Maddox, {Marcus M.} and Singh, {Aman P.} and Lee, {Robin B.} and Hurdle, {Julian G.} and McNeil, {Michael R.} and Lenaerts, {Anne J.} and Bernd Meibohm and Lee, {Richard E.}",
year = "2014",
month = "2",
day = "5",
doi = "10.1371/journal.pone.0087909",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis

AU - Rakesh,

AU - Bruhn, David F.

AU - Scherman, Michael S.

AU - Woolhiser, Lisa K.

AU - Madhura, Dora B.

AU - Maddox, Marcus M.

AU - Singh, Aman P.

AU - Lee, Robin B.

AU - Hurdle, Julian G.

AU - McNeil, Michael R.

AU - Lenaerts, Anne J.

AU - Meibohm, Bernd

AU - Lee, Richard E.

PY - 2014/2/5

Y1 - 2014/2/5

N2 - The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some potential for development as therapeutics against dormant TB bacilli. In previous studies, the pharmacokinetic properties of nitrofuranyl isoxazolines were improved by incorporation of the outer ring elements of the antitubercular nitroimidazole OPC-67683. This successfully increased stability of the resulting pentacyclic nitrofuran lead compound Lee1106 (referred to herein as 9a). In the current study, we report the synthesis and antimicrobial properties of 9a and panel of 9a analogs, which were developed to increase oral bioavailability. These hybrid nitrofurans remained potent inhibitors of Mycobacterium tuberculosis with favorable selectivity indices (>150) and a narrow spectrum of activity. In vivo, the pentacyclic nitrofuran compounds showed long half-lives and high volumes of distribution. Based on pharmacokinetic testing and lack of toxicity in vivo, 9a remained the series lead. 9a exerted a lengthy post antibiotic effect and was highly active against nonreplicating M. tuberculosis grown under hypoxia. 9a showed a low potential for cross resistance to current antitubercular agents, and a mechanism of activation distinct from pre-clinical tuberculosis candidates PA-824 and OPC-67683. Together these studies show that 9a is a nanomolar inhibitor of actively growing as well as nonreplicating M. tuberculosis.

AB - The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some potential for development as therapeutics against dormant TB bacilli. In previous studies, the pharmacokinetic properties of nitrofuranyl isoxazolines were improved by incorporation of the outer ring elements of the antitubercular nitroimidazole OPC-67683. This successfully increased stability of the resulting pentacyclic nitrofuran lead compound Lee1106 (referred to herein as 9a). In the current study, we report the synthesis and antimicrobial properties of 9a and panel of 9a analogs, which were developed to increase oral bioavailability. These hybrid nitrofurans remained potent inhibitors of Mycobacterium tuberculosis with favorable selectivity indices (>150) and a narrow spectrum of activity. In vivo, the pentacyclic nitrofuran compounds showed long half-lives and high volumes of distribution. Based on pharmacokinetic testing and lack of toxicity in vivo, 9a remained the series lead. 9a exerted a lengthy post antibiotic effect and was highly active against nonreplicating M. tuberculosis grown under hypoxia. 9a showed a low potential for cross resistance to current antitubercular agents, and a mechanism of activation distinct from pre-clinical tuberculosis candidates PA-824 and OPC-67683. Together these studies show that 9a is a nanomolar inhibitor of actively growing as well as nonreplicating M. tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=84895526865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895526865&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0087909

DO - 10.1371/journal.pone.0087909

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e87909

ER -